188
Volume 5, Issue 10: Special Issue
(EJAR)
ISSN: 2181-2020
MPHAPP
THE 6TH INTERNATIONAL SCIENTIFIC AND PRACTICAL
CONFERENCE
“
MODERN PHARMACEUTICS: ACTUAL
PROBLEMS AND PROSPECTS
”
TASHKENT, OCTOBER 17, 2025
in-academy.uz
ASSORTMENT ANALYSIS OF LOCAL SYSTEMIC ANTIVIRAL MEDICINES IN
THE REPUBLIC OF UZBEKISTAN BY PRESCRIPTION AND OVER-THE-
COUNTRY STATUS
M.Kh. Egamberdieva
A.A. Rakhimov
Institute of Pharmaceutical Education and Research, Tashkent city, Republik of Uzbekistan
e-mail: maftunaegamberdiyeva797@gmail.com
https://doi.org/10.5281/zenodo.17332642
Relevance:
this study analyzed the market for systemic antiviral drugs and presented the results
using the content analysis method. The data source was the “Drug Audit” program database of the
Republic of Uzbekistan, which records the import and local production of drugs and medical devices
into the country for 2017-2023. The formulation indicators of local systemic antiviral drugs in the
Republic of Uzbekistan were analyzed. Analyzing the results recorded in 2023 based on the results
of this study, it is revealed that 45% (3 million) of the studied market segment in the Republic of
Uzbekistan are non-prescription drugs and 55% (3.6 million) are prescription drugs. The data
presented is of great importance in providing the population and industry experts with an
understanding of the formulation indicators of systemic antiviral drugs, as well as in conducting
government procurement.
Purpose of the study:
to conduct a content analysis of the packaging of systemic antiviral
drugs imported into the pharmaceutical market of the Republic of Uzbekistan according to their
formulation parameters and, based on this, to plan the next stage of marketing or pharmacoeconomic
research.
Materials and methods:
the research method was carried out using the previously widely used
content analysis method.
Results:
the indicators of prescription and non-prescription categories of systemic antiviral
drugs imported into the Republic of Uzbekistan were studied. The results of the study can be seen in
the diagram below.
This chart shows that in the first three years, the import of non-prescription drugs (2017 - 1.95
million; 2018 - 2.2 million; 2019 - 2.18 million) was higher than that of prescription drugs (2017 -
1.71 million; 2018 - 1.2 million; 2019 - 1.4 million). However, by 2020, the number of systemic
antiviral drugs in the pharmaceutical market of our country has increased significantly, and non-
prescription drugs (3.5 million) have significantly replaced prescription drugs (5.1 million). The study
found that this unusual growth in 2020 was due to the unusually high share of over-the-counter
189
Volume 5, Issue 10: Special Issue
(EJAR)
ISSN: 2181-2020
MPHAPP
THE 6TH INTERNATIONAL SCIENTIFIC AND PRACTICAL
CONFERENCE
“
MODERN PHARMACEUTICS: ACTUAL
PROBLEMS AND PROSPECTS
”
TASHKENT, OCTOBER 17, 2025
in-academy.uz
medicines in 2020, in addition to the “Acyclovir”-containing medicines, the “Inosine pranobex” and
“Umifenovir”-containing medicines. In line with the similarly unusually sharp growth in prescription
medicines, the “Acyclovir”-containing medicines and the Remdesivir-containing medicines had a
significant impact. It should be noted that the “Remdesivir”-containing medicines began to be used
in the local pharmaceutical market in 2020, and by 2023 they were not recorded in the market
indicators at all. During the study period 2021-2023, the number of imported prescription drugs (2021
- 3.8 million; 2022 - 4.1 million; 2023 - 3.6 million) continued to exceed the number of imported non-
prescription drugs (2021 - 2.7 million; 2022 - 2.7 million; 2023 - 3 million).
Conclusions:
according to the results of the study, by 2020, the number of imported items of
systemic antiviral drugs will increase sharply, and the import of prescription drugs will exceed the
import of over-the-counter drugs by 2.4 million packages, which can be explained by the pandemic
(Covid-19) that began in our country in 2020. Comparing the first year of our study, 2017, with 2023,
it can be seen that over-the-counter drugs increased from 1.95 million to 3 million, and prescription
drugs increased from 1.71 million to 3.6 million.
